title: 24-hour ambulatory blood pressure monitoring and spirapril in mild to severe essential hypertension: a randomized dose comparison.
abstract: This was a multicentre randomized, double-blind, parallel-group study to compare the antihypertensive efficacy of spirapril at 3 mg with 12 mg once daily, as determined by 24-hour ambulatory blood pressure monitoring (ABPM), in patients with mild to severe essential hypertension. Following a 4-week placebo run-in phase, 52 male and female outpatients, aged 23-67 years with mild to severe essential hypertension [diastolic blood pressure (DBP) > or = 100 mmHg and < 120 mmHg] were randomized to receive spirapril at either 3 mg or 12 mg once daily for 8 weeks. At the end of active treatment and using the standard mercury sphygmomanometer, the number of responders (sitting DBP < 90 mmHg, but decrease > or = 10 mmHg) was the same in both groups (32% and 37%). There were mean decrease in both systolic blood pressure (SBP) and DBP at trough with both 3 mg and 12 mg doses: -9/-7 mmHg and -12/-7 mmHg, respectively. The rate of normalization (trough DBP < or = 90 mmHg) was 12% and 30% with the 3 mg and 12 mg doses, respectively. Of the 44 patients whose daytime ABPM could be compared, one of 20 patients taking 3 mg of spirapril, and 9 of 24 taking 12 mg of spirapril achieved a DBP < or = 90 mmHg for all time intervals while awake. The differences in blood pressure-lowering were significant with both SBP and DBP during the day and at the end of the dosing interval (p < 0.001 and p < 0.01, respectively). The changes from baseline at 24 hours postdose for SBP/DBP were -3/-6 mmHg with 3 mg and -14/-12 mmHg with 12 mg of spirapril.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Internal Medicine, University Hospital, Nijmegen, The Netherlands.
authors.forename: G
authors.initials: G
authors.lastname: Vreugdenhil
authors.forename: G A
authors.initials: GA
authors.lastname: van Montfrans
authors.forename: M C
authors.initials: MC
authors.lastname: Jacobs
authors.forename: J H
authors.initials: JH
authors.lastname: de Bruijn
authors.forename: D P
authors.initials: DP
authors.lastname: Veerman
authors.forename: P N
authors.initials: PN
authors.lastname: van Es
authors.forename: B
authors.initials: B
authors.lastname: Mellein
authors.forename: C
authors.initials: C
authors.lastname: Guitard
authors.forename: T
authors.initials: T
authors.lastname: Thien
authors.forename: P W
authors.initials: PW
authors.lastname: de Leeuw
mesh_terms: D000328:Adult; D000368:Aged; D000804:Angiotensin II / Q000187:drug effects; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D001794:Blood Pressure / Q000502:physiology; D001795:Blood Pressure Determination; D004311:Double-Blind Method; D004656:Enalapril / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic; D007703:Peptidyl-Dipeptidase A / Q000187:drug effects; D012083:Renin / Q000187:drug effects
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000804:Angiotensin II; D004656:Enalapril; C052555:spirapril; D007703:Peptidyl-Dipeptidase A; D012083:Renin